Back to People

Steven Glazer, MD, has 30+ years international experience from pharma-, diagnostic- and biotech industry in Europe and the USA on both operational and executive levels. Steven’s previous assignments include Senior Vice President Development at Bioinvent International AB, Medical Director, Dade Behring USA, Vice President of Development, Zealand Pharma, Director of Haematology at Novo Nordisk AS and Chief Medical Officer at Hansa Medical AB. He has currently part-time assignments as Medical Director, RhoVac AB, Chief Medical Officer, Idogen AB and Board Member and Chair of Scientific Committee, Immunicum AB.

Steven has led the clinical and project development of monoclonal antibodies, recombinant coagulation factors, peptides, vaccines, and small molecules comprising projects from pre-clinical to regulatory approval and commercialization in US, Europe and Japan. He has also led the clinical development of several instrument reagent systems leading to FDA approval. Furthermore, he has extensive experience with FDA and EMA and has conducted numerous clinical phase 1 and 2 proof-of-concept studies. Steven has also been involved in drug licensing deals and due diligence processes.

Therapeutic areas of expertise include haematology, oncology, haemophiia, HIV, and diabetes.

Steven received his MD from the University of Copenhagen.